ORCHIDPHAR

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 29, 2011, titled "Orchid registers strong turnover of Rs 383.59 crore in Q1 FY12".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 37376.02 lacs for quarter ending on 30-JUN-2011 against Rs. 30350 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 1554.25 lacs for the quarter ending on 30-JUN-2011 against Rs. 2161.48 lacs for the quarter ending on 30-JUN-2010.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 14, 2011, titled "Orchid receives US FDA approval for Venlafaxine ER Capsules ANDA".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Orchid's Cephalosporin API manufacturing facility located in Alathur (Chennai) was issued a Closure Notice by the Tamilnadu Pollution Control Board (TNPCB) citing some non-compliance with regard to the disposal of solid waste. The Company is in active dialogue with the TNPCB officials and is confident of resolving the issues and bringing the plant to a fully operational stage at the earliest.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the disclosure under Regulation 8A of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of proceedings of the Postal Ballot process of the Company.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated June 22, 2011, titled "Orchid's state-of-the-art Cephalosporin API manufacturing facility successfully re-inspected by the USFDA".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the Result of the Postal Ballot.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of Voting through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, for seeking their consent to raise long term funds, increase in authorised share capital and amend the Memorandum and Articles of Association of the Company.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Mr. Bala V Balachandran has been inducted into the Board of Orchid as Additional Director with effect from May 18, 2011. The appointment has been approved by the Board at its meeting held on May 18, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the following has been considered at a meeting of the Board of Directors of the Company held on May 18, 2011 :- (1) Raising of long term resources; (2) Increase in Authorised Capital.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Disclosure under Reg.8A(4) of SEBI (Substantial Acquisition of Share and Takeovers) Regulation, 1997.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the dividend on Equity shares, if approved by the Members at the ensuing Annual General Meeting, will be paid / dispatched between August 16, 2011 and August 18, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated May 18, 2011, titled "Orchid Pharma achieves step function increase in performance in FY11; Consolidated topline soars to Rs 1786 crore in FY11; PAT stood at Rs 156 crore in FY11".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 18, 2011 has recommended a dividend of Rs.3/- per share on the equity share of Rs.10/- each.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 171698.61 lacs for year ending on 31-MAR-2011 against Rs. 129872.31 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 15618.72 lacs for the year ending on 31-MAR-2011 against Rs. 33925.38 lacs for the year ending on 31-MAR-2010.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 159467.88 lacs for year ending on 31-MAR-2011 against Rs. 120518.59 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 15948.36 lacs for the year ending on 31-MAR-2011 against Rs. 33133.96 lacs for the year ending on 31-MAR-2010.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Disclosure under Reg.8A(4) of SEBI (Substantial Acquisition of Share and Takeovers) Regulation, 1997.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the details pursuant to the Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of disclosure in terms of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company will be publishing the audited financial results for the year ended March 31, 2011 within a period of 60 days, i.e., on or before May 30, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated January 27, 2011, titled "Orchid Pharma CMD Mr. K Raghavendra Rao awarded the prestigious 'padma Shri' Award by the Government of India".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Mr. R. Sankaran and Mr. Bharat Shah have been inducted into the Board of Orchid as Additional Directors with effect from January 19, 2011. Their appointments have been approved by the Board at its meeting held on January 19, 2011.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated January 19, 2011, titled "Orchid achieves robust increase in performance during Q3 FY11".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 42714.76 lacs for quarter ending on 31-DEC-2010 against Rs. 30883.77 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 5256.61 lacs for the quarter ending on 31-DEC-2010 against Rs. (1685.96) lacs for the quarter ending on 31-DEC-2009.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of disclosure of pledged Shares under Regulation 8A(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 1997.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Media release dated January 10, 2011, titled "Orchid Pharma CMD conferred with Icon of the Year Award by ICWAI".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated November 04, 2010, titled "Orchid redeems Foreign Currency Convertible Bonds (FCCBs) due in November 2010".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Shri R. Narayanan, Chairman has resigned on October 28, 2010 from the Board of Orchid, given his health condition and age. Subsequent to his resignation, Shri K. Raghavendra Rao, Managing Director has been appointed as the Chairman and Managing Director. Mr.Deepak Vaidya who has been on the Board as a nominee of Symphony Capital Partners (Asia) Pte Ltd will continue to be on the Board as an Independent director subsequent to the sale by Symphony Capital Partners (Asia) Pte Ltd. of their shareholding in Orchid. The above

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated October 28, 2010, titled "Orchid registers strong topline growth of 21% during Q2 FY11".

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 36832.34 lacs for quarter ending on 30-SEP-2010 against Rs. 30484.59 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 2401.49 lacs for the quarter ending on 30-SEP-2010 against Rs. (1320.17) lacs for the quarter ending on 30-SEP-2009.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that Shri. Anil Thadani has resigned from the Board of the Orchid Chemicals & Pharmaceuticals Limited with effect from September 28, 2010. Subsequent to his resignation, Shri. Rajgopal Rajkumar, Alternate Director to Shri. Anil Thadani, also vacates the office of Directorship with effect from September 28, 2010.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of disclosure in terms of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of disclosure in terms of SEBI (Prohibition of Insider Trading) Regulations, 1992.

News Verification : The media had reports on September 18, 2010 that the promoters of Orchid Chemicals & Pharmaceuticals Limited may buy 13.02% stake from Ranbaxy Laboratories Ltd. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Orchid Chemicals & Pharmaceuticals Limited has vide its letter inter-alia stated," The current holding of Solrex Pharmaceuticals in Orchid is around 7.92%. We do not have any information wi

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange copies of disclosures in terms of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of Disclosure under Regulation 7(3) of SEBI (Substantial Acquisition of Shares and takeovers) Regulations, 1997.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that "Orchid has received approval from the US Food and Drug Administration (US FDA) for its ANDA (Abbreviated New Drug Application) for Levetiracetam Tablets, 1000 mg."

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on July 21, 2010.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated July 21, 2010 titled "Orchid registers turnover of Rs 331 crore during Q1 FY11"

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 30350 lacs for quarter ending on 30-JUN-2010 against Rs. 30581.89 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 2161.48 lacs for the quarter ending on 30-JUN-2010 against Rs. (2976.05) lacs for the quarter ending on 30-JUN-2009.

Orchid Chemicals & Pharmaceuticals Limited has submitted to the Exchange a copy of the Notice of the Annual General Meeting of the members of the company to be held on July 21, 2010.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Company has received the tentative approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for its generic drug Gemifloxacin Mesylate tablets in 320 mg strength.

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a Press Release dated June 10, 2010 titled "Orchid to acquire US-based marketing company Karalex Pharma, LLC."

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange that the Annual General Meeting of the Company has been proposed to be held on July 21, 2010. Further, the dates for closure of Register of Members for the purpose of Annual General Meeting and for payment of Dividend has been fixed by the Board from July 14, 2010 to July 21, 2010 (both days inclusive).

Orchid Chemicals & Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 27, 2010, titled "Orchid's consolidated turnover for FY10 increase to Rs. 1343 crore".